Expression of Interest










Host Organisations

24th Scientific Meeting of the International Society of Hypertension
34th Annual Scientific Meeting of the High Blood Pressure Research Council of Australia
9th Congress of the Asian-Pacific Society of Hypertension

 


Sponsored Symposiums

Sponsored Symposiums

Sunday 30 September 2012

Medtronic Sponsored Symposium:
1120 – 1240, Bayside Gallery A

 

Symplicity ™ Renal denervation for treatment-resistant hypertension.


Chairs: M. Esler, M. Schlaich
Speakers and Topics:

  • Epidemiology of resistant hypertension and current treatment challenges
  • M. Esler  - Resistant hypertension and the role of the sympathetic nervous system 
  • J. Davies – Performing renal denervation with Symplicity
  • R.E. Schmieder / K. Narkiewicz            – Overview of Symplicity clinical data and future trials (Symplicity HTN-3, Symplicity HF, and the Global Symplicity Registry)
  • M. Esler, R.E. Schmieder - The role of Symplicity renal denervation in modern hypertension management:   Opportunities and challenges from the real world

Takeda Sponsored Symposium:
1330 - 1515, Bayside Gallery A

 

Treating Hypertension and the role of ARBs:  Update on ARBs, Clinical Pharmacology and Clinical Implications.  Chair:  Simon Roger (Australia)

 

Speakers and Topics:

  • Piyamitr Sritara  (Thailand) – Treatment of hypertension in Asia- role of socioeconomic status
  • Peter Meredith (UK) - Comparative pharmacology of ARBs & clinical implications
  • Masatsugu Horiuchi (Japan) – Hypertension treatment in Japan- role of RAS
  • Dominic Sica (USA) – New Developments in the treatment of hypertension- Edarbi/Edarbyclor
  • Chair: Simon Roger (Australia)

Read More

In both developed and emerging economies hypertension is a major cardiovascular risk.   There are numerous options available to treat hypertension with ARBs playing a major role.  However, unmet needs are still prevalent in anti-hypertensive treatment, such as adequate and sustained blood pressure control and better tolerability.  Furthermore, ethnicity and genetic factors, in particular the renin-angiotensin system gene polymorphisms, maybe important in both the development and treatment of hypertension. Thus, treatment of hypertension remains challenging and new treatments are essential to effectively control blood pressure.

During this symposium, several aspects of hypertension treatment will be discussed, including:
• Currently available ARBs and differentiation of these ARBs by pharmacology and molecular mechanisms
• Treatment paradigms in Asian and Western countries
• Factors influencing treatment such as ethnicity and genetics.

• New ARBs and the role of diuretics in the treatment of hypertension- what makes them different?
Monday 1 October 2012

Novartis Sponsored Symposium:
0700 – 0830, Bayside Gallery B

 

Intensifying Hypertension Management: Australian and International Perspectives

 

Speakers:

  • Dr David Calhoun, University of Alabama, USA
  • Prof Simon Stewart,  BakerIDI, Melbourne, Australia

Omron Sponsored Symposium:
1615 – 1715, Bayside Terrace

 

Beyond Blood Pressure: New Era of Cardiovascular Diagnosis

 

Speakers:

  • Stephan Harrap
  • Akira Yamashina
  • Markus Schlaich
Tuesday 2 October 2012

Omron Sponsored Symposium:
1615 – 1715, Bayside Terrace

 

Controversies and Answers in Blood Pressure Monitoring

 

Speakers:

  • Garry Jennings
  • Pat Byrnes
  • Yutaka Imai